CO5611107A2 - Sales de valsartan - Google Patents

Sales de valsartan

Info

Publication number
CO5611107A2
CO5611107A2 CO04086386A CO04086386A CO5611107A2 CO 5611107 A2 CO5611107 A2 CO 5611107A2 CO 04086386 A CO04086386 A CO 04086386A CO 04086386 A CO04086386 A CO 04086386A CO 5611107 A2 CO5611107 A2 CO 5611107A2
Authority
CO
Colombia
Prior art keywords
valsartan
salt
salts
tetrahydrate
polymorphs
Prior art date
Application number
CO04086386A
Other languages
English (en)
Spanish (es)
Inventor
Marti Erwin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5611107A2 publication Critical patent/CO5611107A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CO04086386A 2002-02-04 2004-09-02 Sales de valsartan CO5611107A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35419902P 2002-02-04 2002-02-04

Publications (1)

Publication Number Publication Date
CO5611107A2 true CO5611107A2 (es) 2006-02-28

Family

ID=27734333

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04086386A CO5611107A2 (es) 2002-02-04 2004-09-02 Sales de valsartan

Country Status (17)

Country Link
US (3) US6869970B2 (enExample)
EP (1) EP1474402A1 (enExample)
JP (2) JP4895475B2 (enExample)
KR (3) KR20120054667A (enExample)
CN (2) CN100548993C (enExample)
AU (1) AU2003214054B2 (enExample)
BR (1) BR0307442A (enExample)
CA (2) CA2776902A1 (enExample)
CO (1) CO5611107A2 (enExample)
EC (1) ECSP045221A (enExample)
MX (1) MXPA04007525A (enExample)
NO (1) NO328155B1 (enExample)
NZ (1) NZ534560A (enExample)
PL (1) PL370481A1 (enExample)
RU (1) RU2004126862A (enExample)
WO (1) WO2003066606A1 (enExample)
ZA (1) ZA200405698B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
ATE409476T1 (de) * 2002-06-13 2008-10-15 Novartis Pharma Gmbh Calciumsalze von statinen aus indol
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
AU2004238546A1 (en) * 2003-05-16 2004-11-25 Novartis Ag Pharmaceutical composition comprising valsartan
CN1882334A (zh) * 2003-11-14 2006-12-20 诺瓦提斯公司 用于治疗肾病综合征的at1－受体拮抗剂
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
DE502004002443D1 (de) * 2004-04-15 2007-02-08 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
KR20070074576A (ko) 2004-10-29 2007-07-12 코와 가부시키가이샤 사구체 질환 치료제
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
PE20080991A1 (es) 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
AR082435A1 (es) 2010-08-03 2012-12-05 Novartis Ag Valsartan altamente cristalino
CN103012301B (zh) * 2013-01-05 2015-06-17 江苏施美康药业股份有限公司 缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
ES2099031B1 (es) 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
EE9900377A (et) * 1997-02-28 2000-04-17 Burstein Laboratories, Inc. Labor laserkettas
US6641886B1 (en) * 1999-03-23 2003-11-04 Flexplay Technologies, Inc. Directory read inhibitor for optical storage media
JP2001155346A (ja) * 1999-11-26 2001-06-08 Toshiba Corp 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
SK16372002A3 (sk) 2000-04-24 2003-04-01 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrát
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
US20030207930A1 (en) 2000-07-19 2003-11-06 Erwin Marti Valsartan salts
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Also Published As

Publication number Publication date
KR20110101257A (ko) 2011-09-15
AU2003214054B2 (en) 2007-08-16
CA2474424A1 (en) 2003-08-14
KR20040081178A (ko) 2004-09-20
CN1628106A (zh) 2005-06-15
NO20043660L (no) 2004-10-12
RU2004126862A (ru) 2005-06-27
ECSP045221A (es) 2004-09-28
BR0307442A (pt) 2005-01-04
EP1474402A1 (en) 2004-11-10
AU2003214054A1 (en) 2003-09-02
CN101633646A (zh) 2010-01-27
US20120022268A1 (en) 2012-01-26
CN101633646B (zh) 2012-08-29
HK1139681A1 (en) 2010-09-24
PL370481A1 (en) 2005-05-30
CN100548993C (zh) 2009-10-14
US8329919B2 (en) 2012-12-11
US6869970B2 (en) 2005-03-22
NZ534560A (en) 2007-05-31
NO328155B1 (no) 2009-12-21
JP5303370B2 (ja) 2013-10-02
CA2776902A1 (en) 2003-08-14
US20050101652A1 (en) 2005-05-12
US20030171414A1 (en) 2003-09-11
WO2003066606A1 (en) 2003-08-14
JP2009235086A (ja) 2009-10-15
JP4895475B2 (ja) 2012-03-14
JP2005517696A (ja) 2005-06-16
ZA200405698B (en) 2006-05-31
MXPA04007525A (es) 2004-11-10
US8058301B2 (en) 2011-11-15
KR20120054667A (ko) 2012-05-30
CA2474424C (en) 2013-03-26

Similar Documents

Publication Publication Date Title
CO5611107A2 (es) Sales de valsartan
NO20050542L (no) Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin
AR112669A2 (es) Compuestos inhibidores del cotransportador de sodio y glucosa 2 y compuestos útiles para su preparación
PL2185510T3 (pl) Nowe sole bazedoksyfenu
GB2395946B (en) Method for the production of sodium chloride from seawater
DK1466912T3 (da) 2-acylaminothiazolderivat eller salt deraf
IL150511A0 (en) Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
IL166239A0 (en) 2-cyano-4-fluoropyrrolidine derivative or its salt
IS8217A (is) Bætt framleiðsla rósúvastatínkalsíumsalts
GB2393888B (en) Water supply arrangement for flowerpot or the like
AR046319A1 (es) Sal de tiotropio y composiciones farmaceuticas que la contienen.
IS7969A (is) Pýridínafleiður sem eru gagnlegar við að hamla natríum/kalsíumskiptikerfi
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
WO2005100352A8 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
PE20081402A1 (es) Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura
ATE355255T1 (de) Auflösungshemmende mittel zur herstellung von gereinigten solen
ITMI20042231A1 (it) Cefdinir sale d'ammonio in forma cristallina
AR054131A1 (es) Hidratos de sales alcalino-terreas de irbesartan y su preparacion
UA85218C2 (en) Crystalline form of risedronate monosodium
CA2536886A1 (en) Crystal of 1-methyl carbapenem compound
DE602004014237D1 (de) Herstellungsverfahren von kristallinem Losartan-Kaliumsalz
IT1303734B1 (it) Forma cristallina del diclofenac sale sodico.
PL353712A1 (en) Method of receiving calcium salt monohydrate of 2,5-dihydroxybenzenesulfonic acid
JP2005213235A5 (enExample)
RU2002101454A (ru) Препарат для подавления роста сульфатвосстанавливающих бактерий

Legal Events

Date Code Title Description
FC Application refused